Article Per Year (5 Year)
p-Index From 2021 - 2026
8.459
P-Index
This Author published in this journals
All Journal International Journal of Public Health Science (IJPHS) SAINS MEDIKA : JURNAL KEDOKTERAN DAN KESEHATAN Jurnal Ilmiah Farmasi Jurnal Kebijakan Kesehatan Indonesia Pharmaciana: Jurnal Kefarmasian Indonesian Journal of Pharmaceutical Science and Technology Jurnal Farmasi Klinik Indonesia Jurnal Ilmu Farmasi dan Farmasi Klinik (Journal of Pharmaceutical Science and Clinical Pharmacy) Pharmacon MPI (Media Pharmaceutica Indonesiana) INDONESIAN JOURNAL OF PHARMACY Acta Pharmaceutica Indonesia UNEJ e-Proceeding Journal of Islamic Pharmacy JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA The Indonesian Biomedical Journal Jurnal Farmasi Galenika (Galenika Journal of Pharmacy) Jurnal Penelitian Kesehatan Suara Forikes Jurnal Surya Medika Jurnal Wiyata : Penelitian Sains dan Kesehatan JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice) Jurnal Ilmiah Ibnu Sina (JIIS): Ilmu Farmasi dan Kesehatan Majalah Farmaseutik Pharmasipha Jurnal Farmasi Medica (Pharmacy Medical Journal) PMJ Media Ilmu Kesehatan JSFK (Jurnal Sains Farmasi & Klinis) JFL : Jurnal Farmasi Lampung JPSCR : Journal of Pharmaceutical Science and Clinical Research PHARMACY: Jurnal Farmasi Indonesia (Pharmaceutical Journal of Indonesia) Jurnal Endurance: Kajian Ilmiah Problema Kesehatan Jurnal Farmasi Indonesia Oceana Biomedicina Journal JFIOnline JURNAL MEDIA KESEHATAN PREPOTIF : Jurnal Kesehatan Masyarakat Jurnal Aisyah : Jurnal Ilmu Kesehatan Journal of Pharmaceutical and Health Research Jurnal Insan Farmasi Indonesia Jurnal Farmasi dan Sains Indonesia (JFSI) Jurnal Ilmiah Ibnu Sina (JIIS): Ilmu Farmasi dan Kesehatan Media Farmasi Indonesia Jurnal Farmasi Sains dan Praktis Jurnal Ilmiah Kesmas-IJ (Indonesia Jaya) Riset Informasi Kesehatan Journal of Health Economic and Policy Research (JHEPR) Academic Hospital Journal Kartika : Jurnal Ilmiah Farmasi Jurnal Ilmiah Multidisiplin Keilmuan Mandira Cendikia (JIMK-MC) Journal of Tropical Pharmacy and Chemistry Jurnal Ilmiah Manuntung: Sains Farmasi dan Kesehatan Indonesian Journal of Pharmacology and Therapy Strada Jurnal Ilmiah Kesehatan (SJIK) Jurnal Farmasi Sains dan Terapan (Journal of Pharmacy Science and Practice)
Tri Murti Andayani
Universitas Gadjah Mada
Agriculture, Biological Sciences & Forestry Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Chemistry Civil Engineering, Building, Construction & Architecture Computer Science & IT Decision Sciences, Operations Research & Management Dentistry Economics, Econometrics & Finance Education Environmental Science Health Professions Immunology & microbiology Languange, Linguistic, Communication & Media Law, Crime, Criminology & Criminal Justice Materials Science & Nanotechnology Medicine & Pharmacology Neuroscience Nursing Physics Public Health Social Sciences Veterinary Other

Published : 148 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 148 Documents
Search

 11   12   13   14   15 
THE INFLUENCE OF COST-FACIT AND HEALTH-RELATED QUALITY OF LIFE IN CANCER PATIENTS: A NARRATIVE REVIEW Wulandari, Aprilla Ayu; Andayani, Tri Murti; Endarti, Dwi; Pratiwi, Woro Rukmi
Jurnal Farmasi Sains dan Praktis Vol 11 No 2 (May-August 2025)
Publisher : Universitas Muhammadiyah Magelang

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.31603/pharmacy.v11i2.7220

Abstract

COST-FACIT is a financial toxicity measurement instrument that has been validated in several countries. Financial toxicity is a broad term that includes the costs a patient has to bear after a cancer diagnosis, which impacts personal and family budgets. This has implications for increasing awareness of the financial toxicity experienced by cancer patients so that it can support better policies and funding decisions by hospital management and the government. This article is a Narrative Review on studies regarding the influence of COST-FACIT and HRQoL in cancer patients. Search for English articles using the Pubmed, ScienceDirect, and Google Scholar databases, which were published from 2012 to 2022. Based on the Narrative Review that has been done, there are 19 articles that meet the criteria. In the article there are various HRQoL dimensions that are correlated with COST-FACIT. Dimensions that have a moderate to strong influence are psychological (emotional) and financial because the occurrence of financial toxicity can disrupt family expenses every month. If this continues, it can result in psychological distress for the patients and their family.
Cost-effectiveness of immune checkpoint inhibitors and chemotherapy in triple-negative breast cancer: a scoping review Venanti, Bernadeta Setyo; Rizky Danang Susetyo; Hilmy Irsyadi Hanif; Tri Murti Andayani; Zullies Ikawati
Indonesian Journal of Pharmacology and Therapy Vol 6 No 3 (2025)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.21778

Abstract

Triple-negative breast cancer (TNBC) is an aggressive malignancy associated with poor clinical outcomes and substantial economic burden. Standard chemotherapy treatment offers limited survival benefits, whereas immune checkpoint inhibitors (ICIs) have broadened therapeutic options. This review evaluates the cost-effectiveness of ICIs compared to conventional chemotherapy in TNBC and aims to identify which ICI provides the most favorable economic value. Using the PICO framework, which focuses on TNBC patients receiving chemotherapy as intervention and ICIs as comparators. The primary outcomes include incremental cost-effectiveness ratio (ICER), quality-adjusted life years (QALYs), and/or life years gained (LYG). Thearticles were selected based on the PRISMA strategy. A comprehensive selection of articles published from January 2020 to December 2024 was analyzed from PubMed, Google Scholar, Cochrane, and Scopus. TNBC commonly shows high tumor T-cell infiltration and Programmed Death Ligand-1 (PD-L1) expression, making ICIs such as atezolizumab and pembrolizumab viable treatment options. Atezolizumab improvedprogression-free survival (PFS) but was not found to be cost-effective in Singapore or the U.S. Pembrolizumab, however, significantly improved event-free survival (EFS) and demonstrated cost-effective across multiple countries, including Egypt, the United States of America (USA), and Switzerland. Sacituzumab govitecan, despitesurvival benefits in metastatic TNBC, showed high ICERs and poor cost-effectiveness. Pembrolizumab combined with chemotherapy appears to be more cost-effective than atezolizumab for PD-L1-positive TNBC patients. Meanwhile, sacituzumab govitecan has not been demonstrated to be cost-effective.
The correlation of clinical pathway compliance implementation on clinical outcome and sectio caesarian patient costs in a type c private hospital in Lampung Joko Sunowo; Tri Murti Andayani; Dwi Endarti; Eka Tri Wulandari
Jurnal Aisyah : Jurnal Ilmu Kesehatan Vol 8, No S1: Supplement
Publisher : Universitas Aisyah Pringsewu

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (648.868 KB) | DOI: 10.30604/jika.v8iS1.1756

Abstract

Sectio caesaria births are around 17.6% of all births (Riskesdas, 2018), this figure is higher than the figure recommended by WHO. The high incidence and cost of sectio caesaria can cause problems if they are not managed properly. CA clinical pathway (CP) as a multi-disciplinary management plan for patients with certain diagnoses can be used to improve the quality and efficiency of excellent health services for each individual according to the law’s mandate. This research is research (observational analytic) with cross-sectional design and retrospective method for data collection. The data in this research were all BPJS patients who underwent sectio caesaria for the period of 1 January 2020 to 30 June 2020 according to the inclusion and exclusion criteria in a type C private hospital in Lampung Province. The observations were made on CP forms and patient medical record documents as well as details of treatment costs from BPJS claim data. To see the correlation of compliance implementation with CP and clinical outcomes, the Chi-square test was carried out, the average analysis of CP implementation compliance with costs was carried out using a non-parametric regression test, the correlation of confounding variables on clinical outcomes was tested using Chi-square and Somers tests, and the correlation between confounding variables and total real costs was tested using the ANOVA test. The descriptive analysis found that the average CP implementation compliance of 145 patients (63%) had an average good adherence score (more than 85%) and 85 patients (37%) had low adherence (less than 85%). The points of care education and nutrition counseling as well as treatment or medical intervention have the highest score of 99.57% and the lowest is 0.34% in nursing mobilization/rehabilitation. The description of clinical outcomes of 230 patients with sectio caesaria Length of Stay (LOS) according to CP (less than 3 days) as many as 95 patients and 185 patients with pain scale (VAS 2) and no patients had ILO. The results of the statistical analysis showed that there was no correlation of compliance implementation of CP on clinical outcomes based on the pain scale, LOS, and total real costs (p more than 0.05). The result of the statistical analysis of the confounding variables Age (p 0.015) and treatment class (p 0.00) showed that there was a correlation on the total real costs (p less than 0.05). The conclusion of this research is that there is no correlation of compliance implementation with CP on clinical outcomes and the total real cost of sectio caesaria patients, and there is a correlation between age and class of care on the total real cost of sectio caesaria patients.  Abstrak: Kelahiran sectio caesaria sekitar 17, 6% dari seluruh kelahiran  (Riskesdas, 2018), angka ini lebih tinggi dari angka yang direkomendasikan WHO. Tingginya angka kejadian dan biaya sectio caesaria  dapat menimbulkan permasalahan jika tidak dikelola dengan baik. Clinical pathway (CP) sebagai suatu rancangan penatalaksanaan multi disiplin untuk pasien dengan diagnosis tertentu dapat digunakan dalam upaya meningkatkan kualitas dan efisiensi pelayanan kesehatan yang prima kepada setiap individu sesuai amanat Undang Undang. Penelitian ini adalah penelitian (observasional analitik) dengan desain cross sectional dan metode retrospektif untuk pengambilan data. Data pada penelitian ini adalah seluruh pasien BPJS yang menjalani sectio caesaria periode 1 Januari 2020 sampai 30 Juni 2020 sesuai kriteria inklusi dan eksklusi di sebuah RS swasta tipe C di Provinsi Lampung. Pengamatan dilakukan pada form CP dan dokumen rekam medik pasien serta rincian biaya perawatan dari data klaim BPJS. Untuk melihat hubungan kepatuhan pelaksanaan CP terhadap outcome klinik dilakukan uji Chi square, analisis rata-rata kepatuhan pelaksanaan CP terhadap biaya dilakukan menggunakan uji regresi non parametrik , hubungan variable perancu terhadap outcome  klinik diuji menggunakan uji Chi square dan somers serta hubungan variable perancu terhadap total biaya riil diuji menggunakan uji anova. Analisis deskriptif didapatkan, rata-rata kepatuhan pelaksanaan CP sebanyak 145 pasien (63%) memiliki nilai rata-rata kepatuhan baik (85%) dan 85 pasien (37%) untuk kepatuhan rendah (kurang dari 85%). Poin asuhan edukasi dan konseling gizi serta tatalaksana atau intervensi medis memiliki nilai tertinggi sebesar 99,57% dan terendah sebesar 0,34% pada mobilisasi / rehabilitasi keperawatan. Deskripsi outcome klinik dari 230 pasien sectio caesaria Length of Stay (LOS) sesuai CP (kurang dari 3hari) sebanyak 95 pasien dan 185 pasien dengan skala nyeri (VAS 2) serta tidak didapati pasien yang mengalami ILO.  Hasil analisis statistik menunjukkan tidak adanya hubungan kepatuhan pelaksanaan CP terhadap outcome  klinik yang berdasarkan skala nyeri, LOS,dan total biaya riil  (p lebih dari 0,05 ). Hasil analisis statistik variable perancu usia (p 0,015) dan kelas perawatan (p 0,00) menunjukan ada hubungan terhadap total biaya riil  (p kurang dari 0,05). Kesimpulan pada penelitian ini adalah tidak terdapat hubungan antara kepatuhan pelaksanaan CP terhadap outcome  klinik dan total biaya riil pasien sectio cesaria, serta terdapat hubungan usia dan kelas perawatan terhadap total biaya riil pasien sectio caesaria.
Analisis Biaya dan Luaran Klinik Terapi Remdesivir dibandingkan Favipiravir pada COVID-19 Derajat Sedang: Perspektif Provider Aniq, Laduna; Andayani, Tri Murti; Endarti, Dwi
JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice) Vol 13, No 4
Publisher : Faculty of Pharmacy, Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/jmpf.87168

Abstract

The COVID-19 pandemic cases affect health and the economy and have become a burden for the global community. Effective and specific antiviral for COVID-19 is still controversial and has yet to be found. Antiviral use is the main mitigation strategy that tends to be more cost-effective but varies in effectiveness and cost depending on various factors. This study aims to evaluate the effectiveness, safety, and cost of antiviral therapy in moderate COVID-19. This observational-analytic study used a retrospective cohort design. Subjects were hospitalized patients with moderate COVID-19 who received antivirals in July-October 2021 and January-March 2022. Therapy effectiveness was measured by lowered NLR (Neutrophil-to-Lymphocyte Ratio) to a normal level and length of stay (LOS). Drug safety includes adverse drug events. The cost of therapy was calculated based on the hospital’s perspective (provider), using direct medical costs. A total of 170 patients were divided into two groups (94 patients remdesivir and 76 patients favipiravir). In this arm, there were 45 patients with lowered NLR (21 patients reached the target and 24 patients did not). The effectiveness of favipiravir and remdesivir was 70.6% and 32.1%. Remdesivir may lower NLR (2.92) versus favipiravir (1.55). Favipiravir had a shorter LOS than remdesivir (8 vs 9 days). Adverse drug events observed in remdesivir were nausea (47.9%) and abdominal pain (22.3%), while in favipiravir nausea (53.9%) and vomiting (22.4%). The average total cost of remdesivir is higher than favipiravir (IDR 19,772,985 vs IDR 13,819,727). Favipiravir has higher efficacy and a shorter LOS with a lower average total cost than remdesivir.
Cost-Effectiveness of Length of Stay of Intravenous Aminophylline and Nebulized Salbutamol in Asthma Exacerbations Lorensia, Amelia; Ikawati, Zullies; Andayani, Tri Murti; Maranatha, Daniel
Journal of Tropical Pharmacy and Chemistry Vol. 8 No. 1 (2024): J. Trop. Pharm. Chem.
Publisher : Faculty of Pharmacy, Universitas Mulawarman, Samarinda, Indonesia, 75117, Gedung Administrasi Fakultas Farmasi Jl. Penajam, Kampus UNMUL Gunung Kelua, Samarinda, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.25026/jtpc.v8i1.435

Abstract

Asthma is a heterogeneous disease which is also one of the major health problems in the world. Uncontrolled asthma symptoms will exacerbate asthma, which is the biggest cause of the patient into the ER. Salbutamol is a bronchodilator that belonged to the short-acting beta-2 agonist (SABA), which is an obligatory choice in the management of asthma exacerbations. Unlike the aminophylline group in Indonesia which is still often used widely and rarely appear in the side effects of its use. The main objective of this study was to evaluate the cost-effectiveness of nebulized salbutamol versus intravenous aminophylline for reduction in asthma symptoms, improvement in lung function, and a long hospital stay. The study involved 57 adults asthma exacerbation patients without complication who received treatment in the ER, were studied by using quasi-experimental methods in this study cost-effectiveness analysis to compare intravenous aminophylline (n:27) versus nebulized salbutamol (n:30) therapy to determine the most cost-effective. Intravenous aminophylline therapy was more cost-effective than nebulized salbutamol in reducing the symptoms of asthma and PEF value improvement. Clinical outcome of the length of hospital stay outcome both had the same effective, and cost analysis results showed intravenous aminophylline (US$5.38) cheaper than nebulized salbutamol (US$5.71). intravenous aminophylline was more effective in reducing asthma symptoms than nebulized salbutamol (Pvalue=0.001). Meanwhile, the average decrease in lung function intravenous aminophylline than nebulized salbutamol, although not significantly different (Pvalue=0.507). Aminophylline therapy was more cost-effective in reducing asthma symptoms and improvement in lung function compared nebulized salbutamol in exacerbations asthma patients. But cost-effectiveness researchers need to measure substance abuse outcomes in terms of Quality-Adjusted Life Years (QALY), as this will make their findings more relevant to the development of treatment policy.
Adverse effects of fentanyl/midazolam among patients of intensive care unit (ICU): a narrative review Septiyanti, Windy; Puspita Sari, Ika; Murti Andayani, Tri
Indonesian Journal of Pharmacology and Therapy Vol 5 No 2 (2024)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.11232

Abstract

Patients of intensive care unit (ICU) have a complicated condition due to disease, comorbid, and other risk factors. Some ICU patients need to get an invasive process to reduce pain, anxiety, and support their condition. During an invasive process, including mechanical ventilation which causes pain or anxiety, the patient is givensedative and analgesic agents to support the procedure and reduce the patient’s pain and anxiety. However, the use of fentanyl/midazolam has the potential to cause adverse effects, for instance, hypotension, hypoxia, and delirium in several ICU patients. Several risk factors that can lead to adverse effects are aging, obesity, underlying cardiac disease, and the amount of dosage. Therefore, it is essential to recognize the risk factors and monitor the use of fentanyl/midazolam to prevent the worsening condition of patients.
Pola dan Konsumsi Antibiotik pada Pasien Pneumonia RSUD Abdul Wahab Sjahranie Samarinda Normakiyah; Murti Andayani, Tri; Endarti, Dwi
Jurnal Farmasi Sains dan Terapan (Journal of Pharmacy Science and Practice) Vol. 12 No. 2 (2025): October
Publisher : Faculty of Pharmacy, Widya Mandala Surabaya Catholic University, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33508/jfst.v12i2.7296

Abstract

Antibiotik merupakan terapi utama dalam pengobatan pneumonia. Resistensi antibiotik dapat disebabkan oleh penggunaan antibiotik yang tidak tepat. Penelitian penggunaan antibiotik perlu dilakukan sebagai salah satu langkah mengurangi resistensi antibiotik. Penelitian ini bertujuan untuk memberi gambaran pola dan konsumsi antibiotik pada pasien pneumonia di RSUD Abdul Wahab Sjahranie Samarinda. Penelitian ini merupakan penelitian observasional deskriptif dengan rancangan penelitian cross sectional. Pengambilan data pasien penyakit pneumonia rawat inap secara retrospektif dilakukan berdasarkan catatan rekam medis pasien di RSUD Abdul Wahab Sjahranie Samarinda selama periode 1 Januari 2021 sampai dengan 31 Desember 2022 dengan menggunakan teknik total sampling. Hasil penelitian menunjukkan pola konsumsi antibiotik dengan konsumsi terbanyak periode tahun 2021 dan 2022 yaitu penggunaan antibiotik tunggal yaitu levofloxacin IV. Konsumsi antibiotik pada pasien pneumonia terbanyak adalah levofloxacin dan ceftriaxonee. Nilai DDD levofloxacin berturut-turut adalah 47,01 DDD/100 hari rawat inap dan 32,2 DDD/100 hari rawat inap dan ceftriaxonee dengan nilai DDD berturut-turut 12,26 DDD/100 hari rawat inap dan 20,74 DDD/100 hari rawat inap. Kesimpulan dari penelitian ini adalah pola antibiotik terbanyak adalah antibiotik tunggal yaitu levoflovacin IV dan antibiotik yang termasuk dalam segmen DU 90% pada tahun 2021 dan 2022 meliputi levofloxacin, ceftriaxonee, azithromycin, moxifloxacin dan meropenem.
Karakteristik Pengobatan dan Biaya Medis Langsung Kanker Payudara pada Kemoterapi Rawat Jalan di RSUD Dr. M. Yunus Tahun 2023 Utami, Dika Aryan; Andayani, Tri Murti; Endarti, Dwi
Majalah Farmaseutik Vol 21, No 4 (2025): in press
Publisher : Faculty of Pharmacy, Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/farmaseutik.v21i4.103487

Abstract

Kanker payudara merupakan jenis kanker dengan prevalensi tertinggi di Indonesia dan secara global, yang memerlukan analisis biaya pengobatan untuk mencapai efektivitas terapi. Penelitian ini bertujuan untuk menganalisis karakteristik pengobatan kanker payudara pada pelayanan kemoterapi rawat jalan di RSUD Dr. M. Yunus selama periode 1 Januari hingga 31 Desember 2023 dan merupakan penelitian deskriptif dengan desain penelitian cross-sectional. Data yang digunakan dalam penelitian ini diambil dari SIM RS dan rekam medis pasien, yang kemudian dianalisis menggunakan perangkat lunak RStudio. Hasil penelitian menunjukkan bahwa terdapat 2.268 pelayanan kemoterapi rawat jalan untuk 386 pasien, mayoritas berusia 40–44 tahun. Pengobatan diberikan melalui tiga rute: intravena (IV), oral (PO), dan kombinasi (injeksi dan oral), dengan total 31 regimen pengobatan. Total biaya medis langsung mencapai Rp 5.719.995.986, dengan rata-rata biaya per pasien sebesar Rp 2.522.044. Rute intravena (IV) paling sering digunakan (49,87%), sementara regimen EC-T (Epirubicin, Cyclophosphamide, dan Docetaxel) paling banyak diberikan (32,80%). Regimen Paclitaxel-Trastuzumab memiliki biaya medis langsung tertinggi, yaitu Rp 9.002.322. Penelitian ini memberikan wawasan tentang karakteristik pengobatan kanker payudara di RSUD Dr. M. Yunus dan diharapkan dapat menjadi dasar perancangan kebijakan berbasis data untuk meningkatkan efektivitas pelayanan kesehatan.
Co-Authors . Inayati A.M Wara Kusharwanti Abdul Khodir Jaelani Abdul Mahmud Yumassik Achmad Fudholi Achmad Fudholi Achmad Fudholi Achmad Fudholi admaja, wika Agung Endro Nugroho Agustini, Tiara Tri Ahmad H. Asdie Ahmad Suriyadi Muslim Ahmad, Irfan Aisyah, Noor Akuba, Jusnita Ali Ghufron Mukti Ali Gufron Mukti Amalia Amalia Amalia Amalia Amalia Amalia Ambar Yunita Nugraheni Amelia Lorensia Anak Agung Gede Sugianthara Ani Pahriyani Aniq, Laduna Anisa Zulfa Fatihah Anna Wahyuni Widayanti Anni Anni, Anni Aqnes Budiarti Ari Dwidayati Arief Nurrochmad Arini, Yovita Dwi Arissa Dwiningrum Artemisia, Rahma Astuti, Rini Budi Atsna, Zafria Avrilya Iqoranny Susilo Ayuning Siwi, Mayang Aditya Azalea, Metty Bekti Meilani Nurcahya Belinda Arbitya Dewi Candra Eka Puspitasari Candraningrat, I Dewa Agung Ayu Diva Cecep Kusmana Chairun W Chairun W Chairun Wiedyaningsih Chinthia Sari Yusriana Desy Purnamasari Dewi, Mahmud Carica dharmika wijaya sakti Dhiyan Kusumawati Didik Setiawan Dina Fatma Alia Dinaryanti, Pratiwi Dini Okyaviani Dini, Intan Rahmania Eka Diyan Ajeng Rossetyowati Diyan Ajeng Rossetyowati Djoko Wahyono Djoko Wahyono Dwiningrum, Arissa Dyah, Ria Istamining Eka Kartika Untari Eka Tri Wulandari Elsa Zhenita, Albela Endang Suparniati Endang Suparniati, Endang Endang Yuniarti Endang Yuniarti erna prasetyaningrum Etikasari, Ria Farida Munawaroh Farida, Yeni Ferdinan Jalung Ferdinan Jalung Ferdy Firmansyah Fidiawan, Arie Firda Ridhayani Fita Rahmawati Fita Rahmawati Fitri, Elny Fredie Irijanto Fredie Irijanto Fridly Manawan Gita Mayasari Gunawan Pamudji Widodo Hafizah, Ilmi Nur Halimah Hayul Halimah Hayul Handi Mukti Fahrizal Handi Mukti Fahrizal Haninditya, Beta Hari Kusnanto Hari Kusnanto Haris, Restu Nur Hasanah Herri S. Sastramihardja Hilmy Irsyadi Hanif Hutahaean, Amsaline Vingky I Dewa Putu Pramantara I Dewa Putu Pramantara I Dewa Putu Pramantara S Ibrahim Arifin Ika Alfinnisa Majida Ika Norcahyanti Ika Purwidyaningrum IKA PUSPITA SARI Ika Puspita Sari Ika Puspitasari Ika Puspitasari Ika Puspitasari Ika Trisnawati Ika Trisnawati, Ika Ikakusumawati, Novita Dhewi Imaniar Noor Faridah Imaniar Noor Faridah Inayati Inayati Inayati, Inayati Indriyati Hadi Sulistyaningrum Ingenida Hadning Intan Rahmania Eka Dini Irfanianta Arif Setyawan Irnayanti Irnayanti Irnayanti, Irnayanti Ivanka, Luna Iwan Dwiprahasto Iwan Dwiprahasto Jaelani, Abdul Khodir Jaelani, Abdul Khodir Jaelani, Abdul Qadir Jarir At Thobari Jason Merari Peranginangin Joko Sunowo Kartika Widayati Taroeno Hariadi Kusharwanti, A.M Wara Kusumawati, Dhiyan L. Endang Budiarti, L. Endang Larasati, Laksmy Anggun Lering, Maria Nona Adriani Liliany Fatonah Lingga Ikaditya Lingga Ikaditya, Lingga Listyana, Yanverty Idda Lukman Hakim Luthfan Budi Purnomo Magistasari, Dewi Makmur, Rahmat Maranatha, Daniel Mariana Wahyudi Mariska Sri Harlianti Mariska Sri Harlianti Marlina, Ni Ketut Martodiharjo, Suwaldi Maulidia, Shofia Siza Mawaqit Makani Maya Arfania Mayasari, Gita Megawati Parmasari Metty Azalea Milda Rianty Lakoan Milda Rianty Lakoan Mohamed Izham Mohamed Ibrahim Mohammad Robikhul Ikhsan Mpila, Deby Afriani Mufarrihah Mufarrihah Mufarrihah, Mufarrihah Mukhamad Najib Mukti, Ali Gufron Mulyani, Risya Munawaroh, Farida Murni, Siti Olega Adawiyah Muslimah Muslimah Mustofa Mustofa Nafiah Adiningrum Nanang Munif Yasin Nanang Munif Yasin Natalia Gilarsih Natalia Gilarsih Nawang Wulan Nago Pitasari Neneng Ratnasari Normakiyah Novena Adi Yuhara Novia Ariani Dewi Novianti, Feby Galuh Nur Rasdianah Nurcahya, Bekti Meilani Nurifahmi, Rahmaningtyas Nuring Novita Kusumawati Nurul Adzkia Ghearizky Nurul Ambianti Nurul Hikmah Nurul Latifah Nurul Qiyaam, Nurul Nurul Safitri Nuryanti, Tety Nutrisia Aquariushinta Sayuti, Nutrisia Aquariushinta Octavia, Mega Oetari Oetari Oetari Oetari Okke Putri Shera Oktaviani, Devi Okti Ratna Mafruhah Pahriyani, Ani Pamungkas, Kumbang Nirbhaya Pande Made Desy Ratnasari Parmasari, Megawati Partini Partini Partini Partini, Partini Pramana, Facetha Intan Pratiwi, Woro Rukmi Primadiamanti, Annisa Purnamasari, Vina Purnomo, Luthfan Budi Purwoko, Agus Puspita Sari, Ika Putri Dina Mahera Laily Rahajeng, Bangunawati Rahayu, Asri Rahma, Nazulanita Rahmawati, Anindya Rahmawati, Fita Rahmawati, Fita Rastiti, Liza Ratnasari, Pande Made Desy Renni Simorangkir Ria Etikasari Ria Istamining Dyah Rina Triasih Riskayanti Riswaka Sudjaswadi Riyanta Aribawa Rizaldy Pinzon Rizaldy T Pinzon Rizka Humardewayanti Asdie Rizky Danang Susetyo Rizky Hidayaturahmah Rokhman, Rifqi Rukminingsih, Fef Ryan Astaruddin S, I Dewa Putu Pramantara Safnurbaiti, Dwi Putri Saharuddin, Tria Saputra Sammulia, Suci Fitriani Sampurno Sampurno Sampurno Sampurno Sampurno, Sampurno Santi Andriani Saputra, Andy Kurniawan Saputri, Erlika Sari, Maya Dwi Wulan Sari, Rafika Mutia Sarifudin, Barbara Azalya Satibi Satibi Satibi Satibi Satibi Satibi Satibi Satibi Selamet, Ni Made Dwi Antika Septiyanti, Windy Setiyaningsih, Hermawati Setyawan, Irfanianta Arif Simanullang, Raymon Siradjuddin, Ammar Sri Haryanti Starlista, Viva Sudewi Mukaromah Khoirunnisa Suffiana, Yunita Sugiyanto - Sugiyanto Sugiyanto Sukengtyas, Dyah Atmi Tri Sulistiawaty, Endang Sunarti Sunarti Supanji, Supanji Susi Ari Kristina Susi Ari Kristina Suwendar Suwendar Syahrizal Ramadhani Syaiful Katadi Tety Nuryanti Titik Nuryastuti Titik Sunarni Tri Wijayanti Tria Saputra Saharuddin Tuangrat Phodha Umi Athijah Utami, Dika Aryan Venanti, Bernadeta Setyo Vo Quang Trung widi astuti r Widiastuti Widiastuti Willi Wahyu Timur Winarni Winarni Wirawan Adikusuma Wulandari, Aprilla Ayu Yance Anas Yeni Farida Yopi Rikmasari, Yopi Yovita Dwi Arini Yusriana, Chinthia Sari ZULLIES IKAWATI Zullies Ikawati Zullies Ikawati Zullies Ikawati